U.S. FDA Mulls Joint Action With India’s DCGI For Closer Scrutiny Of Clinical Research Organizations
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - After setting up a full-fledged India office, U.S. FDA is now planning to initiate its Bioresearch Monitoring Program aimed at comprehensive on-site inspections and data audits designed to monitor all aspects of U.S. FDA-regulated research
You may also be interested in...
U.K. Drug Regulator Follows U.S. FDA; Seeks Closer Ties With India's DCGI
MUMBAI - Following U.S. FDA's moves to work closely with the Drug Controller General of India - the Indian drug regulator - the United Kingdom's Medicines and Healthcare products Regulatory Agency has held discussions with the Indian health department officials to build closer relationships
U.K. Drug Regulator Follows U.S. FDA; Seeks Closer Ties With India's DCGI
MUMBAI - Following U.S. FDA's moves to work closely with the Drug Controller General of India - the Indian drug regulator - the United Kingdom's Medicines and Healthcare products Regulatory Agency has held discussions with the Indian health department officials to build closer relationships
U.S. FDA Readies India Staffing; Says India Office To Enhance Speed And Effectiveness Of Regulatory Cooperation
MUMBAI - U.S. FDA has hand picked a few top notch professionals from its global headquarters for positions at the newly planned Mumbai and New Delhi offices. Over the years, these officers have gained experience in drug regulation and investigations through several global postings